Effect of subcutaneous foslevodopa/foscarbidopa therapy on non-motor symptoms in advanced PD patients
Alina Jander, Sarah Bergner, Beate Schönwald, Monika Pötter-Nerger, Carsten Buhmann, Ute Hidding · 2026
Read Effect of subcutaneous foslevodopa/foscarbidopa therapy on non-motor symptoms in advanced PD patients by Alina Jander, Sarah Bergner, Beate Schönwald, Monika Pötter-Nerger, Carsten Buhmann, Ute Hidding (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13246806.txt.
Description
Jander, Bergner, Schönwald, and co-authors examined whether a newer Parkinson's infusion therapy also eases non-motor symptoms, in this 2026 Journal of Neurology study. Foslevodopa/foscarbidopa delivers Parkinson's medication continuously under the skin and is approved for motor swings in advanced disease, but its effects on sleep, pain, mood, and gut problems were poorly documented. The team followed twenty-one day-clinic patients for nine weeks.
Standard non-motor scores improved by roughly a third, a change past the threshold patients can feel, with the largest gains in sleep disturbance, pain, and constipation. Questionnaire scores for gut symptoms, sleep quality, and depression also improved early on. Four patients developed psychotic symptoms, a known risk. The authors call the results encouraging but exploratory, needing controlled trials.
Catalog record
| CREATOR | Alina Jander, Sarah Bergner, Beate Schönwald, Monika Pötter-Nerger, Carsten Buhmann, Ute Hidding |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |